Evidence map›Paper›PMID 26303834›Full record

ArticleJournal of neurology2015

Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study.

Mariano Serrao, Alberto Ranavolo, Carmela Conte, Chiara Davassi, Silvia Mari, Alfonso Fasano, Giorgia Chini, Gianluca Coppola, Francesco Draicchio, Francesco Pierelli

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Neurophysiology of cerebellar ataxias and gait disorders.Clinical neurophysiology practice · 2023
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Mariano SerraoDepartment of Medico-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Latina, Italy. mariano.serrao@uniroma1.it.
Alberto RanavoloDepartment of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL, Monte Porzio Catone, Rome, Italy.
Carmela ConteFondazione Don Gnocchi, Milan, Italy.
Chiara DavassiDepartment of Medico-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Latina, Italy.
Silvia MariFondazione Don Gnocchi, Milan, Italy.
Alfonso FasanoMorton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, ON, Canada.
Giorgia ChiniDepartment of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL, Monte Porzio Catone, Rome, Italy.
Gianluca CoppolaDepartment of Neurophysiology of Vision and Neurophthalmology, G.B. Bietti Foundation-IRCCS, Rome, Italy.
Francesco DraicchioDepartment of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL, Monte Porzio Catone, Rome, Italy.
Francesco PierelliDepartment of Medico-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Latina, Italy.
Istituto Nazionale per l'Assicurazione Contro gli Infortuni sul Lavoro · ITDon Carlo Gnocchi Foundation · ITSapienza University of Rome · ITFondazione G.B. Bietti · ITToronto Western Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the effect of a rotigotine transdermal patch on stationary and non-stationary locomotion in de novo Parkinson disease (PD) patients in an open-label uncontrolled study. A 3-D gait analysis system was used to investigate four different locomotor tasks: steady-state linear walking, gait initiation, gait termination and 180°-turning. A series of gait variables were measured for each locomotor task. PD patients who received rotigotine treatment (4-8 mg) displayed: (1) increased step length, gait speed, cadence and arm oscillations, and reduced double support duration and step asymmetry during steady-state linear gait; (2) increased initial step length during gait initiation; (3) increased final step length and gait speed, and decreased stability index during gait termination; (4) decreased duration of turning and head-pelvis delays during 180°-turning. The main finding that emerges from the present study is that the dopamine agonist rotigotine can improve various aspects of gait in de novo PD patients.

Indexed as

Outcome Assessment, Health CareAgedAged, 80 and overBiomechanical PhenomenaDopamine AgonistsFemaleGait Disorders, NeurologicHumansLocomotionMaleMiddle AgedParkinson DiseaseTetrahydronaphthalenesThiophenesDopamine AgonistsrotigotineTetrahydronaphthalenesThiophenes3-D gait analysisDe novo ParkinsonKinematicsNon-stationary locomotionRotigotine

Identifiers

PMID26303834
OpenAlexW1667178581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.